Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status \< 2.
* Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor
* Patient meets at least 1 of the following criteria:

  * Disease progression despite standard therapies
  * No standard therapies are available or such therapies are not anticipated to result in a durable response
  * Standard therapies are considered unsuitable or have been refused
* Life expectancy \> 12 weeks
* Able to be hospitalized from 1 day prior to the initial dosing until day 15 of the dosing, and from day 27 until day 29 of the dosing

Exclusion Criteria:

* Patient exhibits persistent subjective and objective findings of toxicity ≥ Grade 2 (CTCAE v4.0-JCOG) from the previous cancer treatment with antitumor effect (except of alopecias)
* Received previous treatment with antitumor effect within 21 days prior to the scheduled initial dosing
* Patient had a major surgical procedure within 21 days prior to the scheduled initial dosing or a major surgical procedure scheduled during the course of the study
* Use of an investigational drug or device within 21 days prior to the scheduled initial dosing
* Use of blood transfusion or hematopoietic growth factors within 14 days prior to the scheduled initial dosing
* A positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)
* Known history of a positive test for human immunodeficiency virus (HIV) infection
* Patient has central nervous system (CNS) or leptomeningeal involvement with clinical symptoms